Skip to content Skip to footer
Subscribe Now
NEWS

REGENXBIO Join Forces with Nippon Shinyaku to Develop and Commercialize RGX-121 and RGX-111 for Mucopolysaccharidosis (MPS)

Shots: REGENXBIO & Nippon have partnered to develop RGX-121 (Hunter syndrome; FDA’s accelerated approval expected in late 2025, with ongoing rolling BLA filing) & RGX-111 (P-I/II study for Hurler syndrome) in the US & Asia. The closing is expected in Q1’25 REGENXBIO will get $110M upfront, ~$700M milestones ($40M development & regulatory + $660M…
January 15, 2025

Read more

NEWS

Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

Shots: Gilead has entered into a strategic collaboration with LEO Pharma to develop the latter’s small molecule oral STAT6 programs targeting various inflammatory disorders As per the terms, Gilead secures worldwide rights to develop, manufacture & commercialize LEO’s preclinical STAT6 inhibitors & degrading proteins, with LEO having the option to co-commercialize them for dermatology…
January 13, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (January 06, 2025 – January 10, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below:     Oculis Reports Results from P-II (ACUITY) Study of OCS-05 for Treating Acute Optic Neuritis Read More: Oculis PharmaEssentia Reports Topline Data from P-III (SURPASS-ET) Trial of Ropeginterferon Alfa-2b-Njft (P1101) in Essential…
January 10, 2025

Read more

NEWS

Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases

Shots: Novo & Valo have expanded their partnership to discover & develop 9 more novel drugs for obesity, T2D & CV diseases, utilizing the former’s expertise in cardiometabolic diseases & Valo’s Opal computational platform plus mutual ability in human data & genetics As per the terms, Valo will get upfront, equity & near-term milestones…
January 9, 2025

Read more

NEWS

Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors

Shots: Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) tech Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using…
January 8, 2025

Read more

NEWS

Avenzo Therapeutics Join Forces with DualityBio to Develop AVZO-1418 (DB-1418) for Solid Tumors

Shots: Avenzo Therapeutics and DualityBio have signed an exclusive license agreement to develop, manufacture & commercialize the former’s AVZO-1418/DB-1418 across the globe (excl. Greater China) As per the terms, DualityBio will get $50M upfront, ~$1.15B development, regulatory and commercial milestones as well as tiered royalties in Avenzo’s territory AVZO-1418, an EGFR/HER3-targeting ADC developed…
January 8, 2025

Read more

Load more